Inhibition and interaction of cytochrome P450 of Candida krusei with azole antifungal drugs

Journal of Medical and Veterinary Mycology

Volumn 35, Issue 1, 1997, Pages 19-25

  Venkateswarlu, K ^a   Denning, D W ^b   Kelly, S L ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; ENZYME; ERGOSTEROL; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; STEROL 14ALPHA DEMETHYLASE; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BIOSYNTHESIS; CANDIDA KRUSEI; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG METABOLISM; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OPPORTUNISTIC INFECTION; SPECTROSCOPY;

CANDIDA; HUMAN IMMUNODEFICIENCY VIRUS; ISSATCHENKIA ORIENTALIS;

EID: 79961221512     PISSN: 02681218     EISSN: None     Source Type: Journal    
DOI: 10.1080/02681219780000821     Document Type: Article

References (21)

1. Kelly SL, Kelly DE. Molecular studies on azole sensitivity in fungi. In: Maresca B, Kobayashi GS, Yamaguchi H, eds. Molecular Biology and Application to Medical Mycology. Berlin: Springer, 1993: 199-213.
2. Beck-Sague C, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal-infections in the United States, 1980-1990. J Infect Dis 1993; 167: 1247-51.
3. Dupont B. Invasive fungal infections caused by yeasts as emerging pathogens. Infect Dis Clin Prac 1994; 3 (Suppl. 2): S78-S82.
4. Wingard JR. Changes in the spectrum of fungal infections in bone marrow transplant patients. Infect Dis Clin Prac 1994; 3 (Suppl 2): S83-S89.
5. Hay RJ. Overview of the treatment of disseminated fungal infections. J Antimicrob Chemother 1991; 28 (Suppl. B): 17-25.
6. Lynch ME, Sobel JD. Comparative in vitro activity of antimycotic agents against pathogenic vaginal yeast isolates. J Med Vet Mycol 1994; 32: 267-274.
7. Morace G, Manzara S, Dettori G. In vitro susceptibility of 119 yeast isolates to fluconazole, 5-fluorocytosine, amphotericin B and ketoconazole. Chemotherapy (Basel) 1991; 37: 23-31.
8. Troke PF. In vitro and experimental in vivo activities of fluconazole against some fungi causing cutaneous mycoses. In: Rippon JW, Fromtling RA, eds. Cutaneous Antifungal Agents. New York: Marcel Dekker, 1993: 199-214.
9. Marichal P, Gorrens J, Coene MC, Le Jeune L, Vanden Bossche H. Origin of differences in susceptibility of Candida krusei to azole antifungal agents. Mycoses 1995; 38: 111-17.
10. Vanden Bossche H, Marichal P, Gorrens J, et al. Interaction of azole derivatives with cytochrome P450 isozymes in yeast, fungi, plants and mammalian cells. Pest Sci 1987; 21: 289-306.
11. Vanden Bossche H, Marichal P, Gorrens J, Geerts H, Janssen PAJ. Mode of action studies. Basis for the search of new antifungal drugs. Ann N Y Acad Sci 1988; 544: 191-207.
12. Ballard SA, Kelly SL, Ellis SW, Troke PF. Interaction of microsomal cytochrome P-450 isolated from Aspergillus fumigatus with fluconazole and itraconazole. J Med Vet Mycol 1990; 28: 327-34.
13. Guan J, Braks HMJ, Kerkenaar A, De Waard MA. Interaction of microsomal cytochrome P450 isozymes isolated from Penicillium italicum with DMI fungicides. Pest Biochem Physiol 1992; 42: 24-34.
14. Wardel HM, Law D, Moore CB, Mason C. Denning DW. In vitro activity of D0870 compared with those of other azoles against fluconazole-resistant Candida spp. Antimicrob Agents Chemother 1995; 39: 868-71.
15. Venkateswarlu K, Denning DW, Manning NJ. Kelly SL. Resistance to fluconazole in Candida albicans from AIDS patients correlated with reduced intracellular accumulation of drug. FEMS Microbiol Lett 1995; 131: 337-41.
16. Omura T, Sato R. The carbon monoxide-binding pigment of liver microsomes 1. Evidence for its hemoprotein nature. J Biol Chem 1964; 239: 2370-8.
17. Yoshida Y. Cytochrome P-450 of fungi: Primary target for azole antifungal agents. In: McGinnis MR, ed. Current Topics in Medical Mycology, vol. 2. New York: Springer-Verlag. 1988: 388-418.
18. Kapteyn JC, Pillmoor JB, De Waard MA. Isolation of microsomal cytochrome-P450 isozymes from Ustilago maydis and their interaction with sterol demethylation inhibitors. Pest Sci 1992; 34: 37-43.
19. Venkateswarlu K, Denning DW, Manning NJ. Kelly SL. Comparison of D0870, a new triazole antifungal agent, to fluconazole for inhibition of Candida albicans cytochrome P-450 by using in vitro assays. Antimicrob Agents Chemother 1996; 40: 1382-6.
20. Hitchcock CA, Dickinson K, Brown SB, Evans EG, Adams DJ. Interaction of azole antifungal antibiotics with cytochrome P-450-dependent 14α-sterol demethylase purified from Candida albicans. Biochem J 1990; 266: 475-80.
21. Vanden Bossche H, Marichal P, Geerts H, Janssen, PAJ. The molecular basis for itraconazole's activity against Aspergillus fumigatus. In: Vanden Bossche H, MacKenzie DWR, Cauwenbergh G, eds. Aspergillus and Aspergillosis. New York: Plenum Press, 1988: 171-97.